AbCellera Biologics Inc vs SoFi Technologies Inc — how do they compare? AbCellera Biologics Inc trades at $9.15 (market cap $2.85B), while SoFi Technologies Inc trades at $17.98 (market cap $23.40B). The key difference: SoFi Technologies Inc is far larger — about 8.2× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | SOFI | |
|---|---|---|
Market Cap | $2.85B | $23.40B |
Sector | Health | Financials |
52-Week High | $9.76 | $32.21 |
52-Week Low | $2.78 | $15.15 |
Enterprise Value | $2.45B | — |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
SoFi Technologies (SOFI) trades at $18.38, up 1.55% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong Q2 2026 results, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75–$4.85 billion, though EBITDA and earnings outlooks were maintained. The stock's valuation shows a P/E of 37.51 and P/S of 5.73, reflecting growth expectations amid profitability improvements.
The outlook for SOFI is cautiously optimistic, driven by robust member growth, cross-selling success, and a diversified revenue stream. Key opportunities include continued execution on the 'everything app' strategy and potential upside to the $19.50 consensus price target. Risks involve reliance on lending growth, pressure on Technology Platform margins, and sensitivity to Federal Reserve rate decisions. Investors should weigh strong fundamentals against high valuation multiples and competitive fintech pressures.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →